ReviewAnnals of gastroenterology
Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned.
Review in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Inflammatory Bowel Disease: Clinical Diagnosis and Pharmaceutical Management.Medical research archives · 2023Article
- Canakinumab might be Protective against Severe COVID-19 for Patients with Autoinflammatory Disorders.Mediterranean journal of rheumatology · 2022Article
- Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview.Medicina (Kaunas, Lithuania) · 2022Review
- Intestinal Protein Characterisation of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in Inflammatory Bowel Disease (IBD) and Fatal COVID-19 Infection.Inflammation · 2022Article
- COVID-19 pandemic and inflammatory bowel disease from patients' perspective: A survey from COVID epicenter in India.JGH open : an open access journal of gastroenterology and hepatology · 2022Article
- Management of inflammatory bowel disease in the COVID-19 era.Intestinal research · 2022Review
- Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study.Journal of Korean medical science · 2021Article
- Capsule Endoscopy in Crohn's Disease-From a Relative Contraindication to Habitual Monitoring Tool.Diagnostics (Basel, Switzerland) · 2021Review
- Therapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axis.World journal of gastroenterology · 2021Review
- Impact of the COVID-19 pandemic on inflammatory bowel disease patients: A review of the current evidence.World journal of gastroenterology · 2021Review
- Evaluating IBD Patient-Initiated Electronic Communication During the SARS-CoV-2 Pandemic: A Single-Center Study.Digestive diseases and sciences · 2021Article
- Successful Distancing: Telemedicine in Gastroenterology and Hepatology During the COVID-19 Pandemic.Digestive diseases and sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current outbreak of COVID-19 pandemic caused by SARS-CoV-2 has affected nearly 188 countries. Patients with severe COVID-19 are more commonly elderly and suffer from comorbidities such as hypertension, diabetes mellitus, coronary artery disease, chronic pulmonary disease, obesity, and cancer. Inflammatory bowel disease (IBD) affects as many as 6.8 million people globally, and a significant proportion of them are treated with immunosuppressants. Hence, there is an ongoing concern over the impact of COVID-19 on IBD patients and their susceptibility to it. So far, there are about 1439 IBD patients in the Surveillance Epidemiology of Coronavirus under Research Exclusion (SECURE-IBD) registry reported to be infected with SARS-CoV-2. There are many unique challenges and dilemmas that need to be taken into account when managing an IBD patient with COVID-19. The management of each patient should be individualized. The IBD societies and experts have strongly recommended that patients should not discontinue their IBD medications. If the patients have symptoms of COVID-19 or IBD flare-up, they are recommended to call their IBD physician first to discuss their medication. In addition, IBD patients are urged to practice social distancing strictly to minimize the chances of infection. As COVID-19 is rapidly evolving, our experience and understanding of its impact on the IBD population may potentially change in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.